Jeffrey M. Leiden - Feb 1, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Executive Chairman, Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 1, 2022
Transactions value $
-$1,529,753
Form type
4
Date filed
2/3/2022, 03:19 PM
Next filing
Feb 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +28.4K +57.13% $0.00 78.2K Feb 1, 2022 Direct F1
transaction VRTX Common Stock Award $0 +20.9K +26.75% $0.00 99.2K Feb 1, 2022 Direct F2
transaction VRTX Common Stock Award $0 +17.4K +17.59% $0.00 117K Feb 1, 2022 Direct F3
transaction VRTX Common Stock Tax liability -$1.53M -6.28K -5.38% $243.63 110K Feb 2, 2022 Direct
holding VRTX Common Stock 440 Feb 1, 2022 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/17/2022.
F3 Restricted stock unit award that fully vested upon grant.

Remarks:

Exhibit 24 - Power of Attorney